AACR

Source: www.medicalnewstoday.com --- 9 days ago
As the scientific partner to Stand Up To Cancer (SU2C), an unprecedented collaboration uniting the major television networks, entertainment industry executives, celebrities and prominent leaders in cancer research and patient advocacy, the ...

Source: www.medicalnewstoday.com --- 14 days ago
The American Association for Cancer Research is currently accepting applications for grants designed to help drive research advances in the treatment of bladder cancer, the fourth most commonly diagnosed cancer in men and the eighth in women. ...

Source: www.medicalnewstoday.com --- 34 days ago
Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) will be presenting its lead cancer technology at this prestigious symposium in Geneva Switzerland in October 2008. Targeted initially for brain tumors, this technology is a major breakthrough in inhibiting glycolysis, a process many tumor cells, but not normal cells, require for growth and survival. ...

Source: www.medicalnewstoday.com --- 29 days ago
The American Association for Cancer Research (AACR), in partnership with Susan G. Komen for the Cure, is currently accepting nominations for the 2008 Susan G. Komen for the Cure- AACR Outstanding Investigator Award for Breast Cancer Research. ...

Source: www.newswise.com --- 23 days ago
American Association for Cancer Research (AACR) Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.) will receive a degree Honoris Causa (h.c.) in Medicine and Surgery from the University of Catania in Sicily on Friday, July 4, 2008. This honorary doctorate is Foti's second and recognizes her distinguished contributions to advancing the field of cancer research worldwide. ...

Source: www.philanthropyjournal.org --- 8 days ago
Beverly W. Aisenbrey and Tyler E. Jacks named trustees of AACR Foundation for the Prevention and Cure of Cancer. read more ...

Source: www.primenewswire.com --- 3 days ago
REDWOOD CITY, Calif., July 22, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine: Cancer Clinical Trials and Personalized Medicine, being held July 20-23, 2008, at the Hyatt Regency Hotel in Monterey, CA. Translational research with the incorporation of laboratory scientific breakthroughs into the medical treatment of cancer is a priority of the AACR which views this conference, and others like it, as a forum for current advances in translational cancer medicine and progress against cancer. ...

Source: www.fwicki.com --- 14 days ago
PHILADELPHIA, July 9, 2008--The http://www.AACR.org ">American Association for Cancer Research (AACR) is currently accepting applications for grants designed to help drive research advances in the treatment of bladder cancer, the fourth most commonly ... ...

Source: www.thefightagainstcancer.com --- 27 days ago
Perhaps the best way to fight cancer is to prevent it from developing in the first place. The latest biological, medical and social research behind cancer prevention will be the focus of the American Association for Cancer Research’s Sixth Annual International Conference on Frontiers in Cancer Prevention Research, to be held December 5 to 8 [...] ...

Source: www.ackc.org --- 49 days ago
ACKC attended the AACR Conference, which took place April 12-16 in San Diego. 29,000 researchers, advocates, and other interested members of the public attended. The following are summaries of some of the presentations. AV-951 in Phase 1 Trial in the Netherlands At the American Association for Cancer Research in April 2008, Ferry Eskens of the Erasmus Medical Center in Rotterdam presented in, an oral session, the results of a Phase 1, single-center trial of the anti-angiogenic drug AV-951 in 41 solid tumor cancer patients, 9 of whom were RCC patients (others included colon, lung, pancreas, and other tumor sites). AV-951 is a highly potent drug that has inhibitory activity against VEGF Receptors 1, 2, and 3. The objectives of the trial were to determine the maximum tolerated dose and dose limiting toxicities. Dosage levels were given of 1 mg, 1.5 mg, and 2 mg per day. Response read more ...

Source: www.medicalnewstoday.com --- 3 days ago
Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA. ...

Source: www.medicalnewstoday.com --- 2 days ago
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA. ...

Source: www.medicalnewstoday.com --- 25 days ago
Through the generous philanthropic support of the Littlefield 2000 Trust, the American Association for Cancer Research (AACR) is pleased to announce three recipients of the 2008 Jeannik M. Littlefield-AACR Grants for Metastatic Colon Cancer Research, totaling $1.8 million. In its third year, this competitive funding program is focused on high impact grants to accelerate the discovery and development of new treatments for metastatic colon cancer. ...

Source: www.eurekalert.org --- 29 days ago
( American Association for Cancer Research ) Through the generous philanthropic support of the Littlefield 2000 Trust, the American Association for Cancer Research is pleased to announce three recipients of the 2008 Jeannik M. Littlefield-AACR Grants for Metastatic Colon Cancer Research, totaling $1.8 million. ...

Source: www.newswise.com --- 29 days ago
Through the generous philanthropic support of the Littlefield 2000 Trust, the American Association for Cancer Research (AACR) is pleased to announce three recipients of the 2008 Jeannik M. Littlefield-AACR Grants for Metastatic Colon Cancer Research, totaling $1.8 million. In its third year, this competitive funding program is focused on high impact grants to accelerate the discovery and development of new treatments for metastatic colon cancer. ...

Source: www.labcanada.com --- 15 days ago
Philadelphia, PA - The American Association for Cancer Research (AACR) says it is currently accepting applications ... [ Full Story ] ...

Source: catalogablog.blogspot.com --- 23 days ago
Some more articles by Martha Yee are now available. Integration of Nonbook Materials in AACR2 . Cataloging & Classification Quarterly 1983; 3:1-18. Attempts to Deal With the Crisis in Cataloging at the Library of Congress in the 1940's . Library Quarterly 1987 Jan; 57:1-31. What is a Work? In: The Principles and Future of AACR: Proceedings of the International Conference on the Principles and Future Development of AACR, Toronto, Ontario, Canada, October 23-25, 1997 . Ed., Jean Weihs. Ottawa: Canadian Library Association; Chicago: American Library Association, 1998: 62-104. Editions: Brainstorming for AACR2000 . In: The Future of the Descriptive Cataloging Rules: Papers from the ALCTS Preconference, AACR2000, American Library Association Annual Conference, Chicago, June 22, 1995 . Ed., Brian E.C. Schottlaender. (ALCTS Papers on Library Technical Services and Collections, no. 6) Chicago: American Library Association, 1998: 40-65. Viewpoints: One Catalog or No Catalog? ALCTS Newsletter 1999; 10:4:13-17. Lubetzky's Work Principle . In: The Future of Cataloging: Insights from the Lubetzky Symposium, April 18, 1998, University of California, Los Angeles . Ed., Tschera Harkness Connell, Robert L. Maxwell. Chicago: American Library Association, 2000. ...

Source: saci.uthscsa.edu --- 33 days ago
Start: 12/10/2008 - 8:00am End: 12/14/2008 - 4:00pm The 2008 San Antonio Breast Cancer Symposium (SABCS) will be the first Symposium presented by the CTRC, AACR, and the Baylor College of Medicine. The driving force behind the new collaboration is the shared mission of the organizations to advance progress against breast cancer. By combining their respective strengths, the 2008 San Antonio Breast Cancer Symposium will encompass the full spectrum of breast cancer research and facilitate the rapid transition of new knowledge into improved care for breast cancer patients. ...

Source: www.roswellpark.org --- 32 days ago
Roswell Park will host the AACR Centennial Symposium: The Future of Cancer Research: Science and Patient Impact on October 27 - 28, 2008. ...

Source: networks.feedburner.com --- 53 days ago
At the annual meeting of the American Association for Cancer Research (AACR) last month, researchers from GeneNews Corp. reported that the probability of colorectal cancer (CRC) in asymptomatic patients can be accurately stratified by RNA expression profiling of six genes in whole blood [1]. The company focuses on developing blood-based biomarker tests for the early [...] ...